Tiziana Life Sciences CEO Discusses COVID-19 Trial Data in Exclusive Interview

Tiziana Reports Positive Data from the Clinical Study of Nasal Administration with Foralumab, its proprietary fully human anti-CD3 monoclonal antibody, in COVID-19 Patients in Brazil

New York/London, 26 January 2021 – Tiziana Life Sciences plc (Nasdaq: TLSA / LSE: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and

AIM Delisting and Admission to the Standard Listing Segment of Main Market

Tiziana announces appointment of Dr Neil Graham MBBS, MD, MPH as Chief Medical Officer

NEW YORK and LONDON – 11 January 2021 (GLOBE NEWSWIRE) – Tiziana Life Sciences plc (NASDAQ: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative

Tiziana announces completion of the clinical trial with nasally administered Foralumab, its proprietary fully human anti-CD3 monoclonal antibody, for the treatment of COVID-19 patients in Brazil

Tiziana Announces Initiation of Clinical Trial for COVID-19 Patients in Brazil with Nasally Administered Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody

London, New York, 26 October 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation